DIRS.INFO The most relevant business & tech news

☆ Disney's dispute with Charter is a lose-lose, underscoring just how broken legacy TV has become
▼ + stars: | 2023-09-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +5 min

The almost weeklong stalemate between Disney and Charter lays bare the broken business model around distributing legacy television in the age of cord-cutting. In the talks, Charter agreed to shell out more than the $2.2 billion annually it paid Disney under the old carriage deal. DIS 1M mountain Walt Disney stock performance month-to-date. Linear TV is an issue for Disney. However, we would like to see a quick end to the Charter dispute and to see Iger resolve Disney's challenging position in the traditional linear TV market.

Persons: Walt Disney, Bob Iger, Jim Cramer, Iger, Disney, Jim Cramer's, Jim Organizations: Hollywood, Charter Communications, Disney, Charter, ESPN, ABC, Spectrum's, U.S, Hulu, Walt Disney, Warner Bros Discovery, JPMorgan, The, CNBC, SportsCenter, ESPN Headquarters, Washington Post, The Washington Post, Getty

☆ Disney, Charter in talks for new distribution agreement
▼ + stars: | 2023-09-01 | by ( ) www.reuters.com time to read: +1 min

A screen shows the logo and a ticker symbol for The Walt Disney Company on the floor of the New York Stock Exchange (NYSE) in New York, U.S., December 14, 2017. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsAug 31 (Reuters) - Disney (DIS.N) said on Thursday that the company is in negotiations with Charter Communications (CHTR.O) for a new agreement after Disney pulled ESPN, ABC and other cable channels off Charter-owned Spectrum's cable service. Charter will host a webcast on Friday to discuss the status of its distribution agreement with Disney, the company said in a statement. Minutes later, a message appeared on the screen informing viewers that Disney had removed its programming, social media posts said. Cable operator Charter Communications (CHTR.O) serves more than 32 million customers in 41 states through its Spectrum brand, according to its website.

Persons: Brendan McDermid, Disney, Akanksha, Nivedita Organizations: Walt Disney Company, New York Stock Exchange, REUTERS, Disney, Charter Communications, ESPN, ABC, Spectrum, U.S, Twitter, Cable, Disney Entertainment, Thomson Locations: New York, U.S, Bengaluru

☆ Assa, Spectrum Brands reach settlement with US on deal
▼ + stars: | 2023-05-05 | by ( ) www.reuters.com time to read: +1 min

May 5 (Reuters) - Sweden's Assa Abloy AB (ASSAb.ST), the world's No. The Justice Department last year sued to block the proposed deal by Assa Abloy to buy the Spectrum Brands HHI division, which makes residential door hardware, saying the deal could lead to higher prices. Assa Abloy makes Yale, August and EMTEK brands, while Spectrum's division makes the Baldwin and Kwikset brands. In a separate statement, Fortune said it will go ahead with the purchase of businesses from Assa Abloy for $800 million. Assa Abloy agreed in December to sell the businesses to Fortune in a bid to resolve the U.S. antitrust issues.

☆ Big investor in Credit Suisse bonds says 'bail-in' system worked
▼ + stars: | 2023-03-22 | by ( Herbert Lash | ) www.reuters.com time to read: +3 min

The firm's exposure to Credit Suisse AT1s represented 1.32% of Spectrum's assets under management (AUM) on Feb. 28. In 2021 and early 2022 Spectrum held about $400 million of Credit Suisse AT1 bonds, Jacoby said. The Credit Suisse debt represents about 12% of the benchmark for CoCos, a massive slice of the ICE BofA U.S. dollar contingent capital index (.MERCOCO), he said. "We had been paring back in Credit Suisse, had an internal negative outlook for a little over a year." "This is a Credit Suisse event and this is a Swiss bank regulation event, this is not a global disaster for CoCos."

☆ U.S. FDA declines to approve Spectrum's lung cancer drug
▼ + stars: | 2022-11-25 | by ( ) www.reuters.com time to read: +1 min

Nov 25 (Reuters) - Spectrum Pharmaceuticals Inc (SPPI.O) said on Friday the U.S. Food and Drug Administration (FDA) declined to approve its experimental lung cancer drug due to inadequate data, prompting the drugmaker to cut jobs. The company said it will no longer focus on developing the drug, poziotinib, for treating non-small cell lung cancer (NSCLC) with a rare genetic mutation that affects 2%-4% of the cancer patients. They have fallen 42.5% since an expert panel to the FDA recommended against the drug's approval in September. Nevada-based Spectrum said it will cut 75% of its research and development workforce and focus on its other cancer drug, Rolvedon. Reporting by Khushi Mandowara; Editing by Krishna Chandra Eluri, Shounak Dasgupta and Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

☆ U.S. FDA panel votes against Spectrum's lung cancer drug
▼ + stars: | 2022-09-22 | by ( ) www.reuters.com time to read: +2 min

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File PhotoSept 22 (Reuters) - Advisers to the U.S Food and Drug Administration on Thursday voted against recommending Spectrum Pharmaceuticals' (SPPI.O) experimental drug for the treatment of patients with a form of non-small cell lung cancer. The FDA panel voted 9 to 4 against the oral drug, poziotinib, citing marginal efficacy, high level of toxicities, and lack of dose optimization. Poziotinib is intended to treat non-small cell lung cancer (NSCLC) with a rare genetic mutation that affects 2-4% of total patients with NSCLC. There is no prior FDA-approved treatment for the rare lung cancer, and the patients suffering from the disease are given treatments similar to those with non-small cell lung cancer without the mutation.

Search resuls for: "Spectrum's"

6 mentions found